Skip to main content


Fig. 7 | Journal of Experimental & Clinical Cancer Research

Fig. 7

From: A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells

Fig. 7

Effects of M802 and M806 on tumor growth in vivo. (a) Prophylactic treatment of NCI-N87 tumors in a subcutaneous xenograft model in NOD/SCID mice reconstituted with human CIKs. (b) Prophylactic treatment of B16-HER2 tumors in a syngeneic model in C57BL/6 mice which were subcutaneously inoculated with 3.0 × 106 B16-HER2 cells. Data indicate mean tumor volumes ± SD. (c) Isolated tumor tissues were stained with anti-mouse CD3 antibody or anti-mouse CD4 antibody or anti-mouse CD8 antibody and analyzed by IHC. We calculated the proportion of CD3-, CD4-, and CD8-positive cells in the total cells and selected a representative image (20×) from each group. (d) PK profile of M802. A single dose (8 mg/kg) of Herceptin (n = 6) or M802 (n = 6) was intravenously injected into BALB/C mice. Serum samples were collected at different timepoints and detected by ELISA. Values indicate means ± SD. *P < 0.05, **P < 0.01

Back to article page